Michael Cannon
Michael Cannon is the director of health policy studies at the Cato Institute, a libertarian think tank based in Washington, D.C. He is known for his expertise in health care policy, particularly regarding the implications of government intervention in the pharmaceutical market. Cannon has been vocal about the potential negative consequences of price control measures, arguing that similar policies in other sectors have historically led to shortages and inefficiencies.
Not in the pool (under ¢1).
Recent news mentions
Michael Cannon, the director of health policy studies at the libertarian Cato Institute, criticized the proposal.
Republicans balk at Trump’s health care proposal before it’s even released
United States· 2025-11-25
Michael Cannon stated that extending the enhanced subsidies would likely depress Republican turnout in the midterms.
The health care struggle is sharpening this fundamental tension in the GOPUnited States· 2025-11-23
Michael Cannon, director of health policy studies at the Cato Institute, discusses the impact of Obamacare on healthcare prices.
Americans brace for healthcare premium increases amid ACA subsidy uncertaintyUnited States· 2025-11-19
Michael Cannon from the Cato Institute stated that Obamacare has led to skyrocketing premiums.
Der Shutdown ist ein Showdown über Obamacare
Switzerland· 2025-10-16
Michael Cannon discussed the anti-establishment backlash affecting public health and the medical community.
Why Democrats see health care as a prescription for revivalUnited States· 2025-09-28
Michael Cannon, Director of Health Policy Studies at the Cato Institute, stated that it is reasonable for taxpayers to insist that everyone in the Medicaid program who can contribute do so.
White House blocks illegal immigrants from accessing federal benefit programsUnited States· 2025-07-11
Michael Cannon, director of health policy studies at the Washington-based libertarian-leaning Cato Institute think tank, commented on the implications of price controls.
President Donald Trump's effort to lower drug costs amounts to price control, expert saysUnited States· 2025-05-14
